We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+10.49%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$11.9B
AUM Growth
+$2.55B
(+27%)
Cap. Flow
+$1.81B
Cap. Flow
% of AUM
15.19%
Top 10 Holdings %
Top 10 Hldgs %
28.34%
Holding
1,181
New
44
Increased
774
Reduced
301
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$294M |
| 2 |
Apple
AAPL
|
+$74.6M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$68.1M |
| 4 |
Tesla
TSLA
|
+$64.9M |
| 5 |
Microsoft
MSFT
|
+$51.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$12.3M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$8.37M |
| 3 |
CLR
CONTINENTAL RESOURCES INC.
CLR
|
+$7.53M |
| 4 |
ASML
ASML
|
+$7.05M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$6.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.81% |
| 2 | Financials | 13.96% |
| 3 | Healthcare | 11.37% |
| 4 | Energy | 7.72% |
| 5 | Consumer Discretionary | 3.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Loews
L
$23.9B
| $4.43M | 0.04% |
75,898
+7,191
| +10% | +$401K |
|
|
DAWN
402
DELISTED
Day One Biopharmaceuticals
DAWN
| $4.42M | 0.04% |
205,446
+60,812
| +42% | +$1.25M |
|
403
JD.com
JD
$44.6B
| $4.41M | 0.04% |
78,623
-42,924
| -35% | -$2.16M |
|
|
CDMO
404
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $4.4M | 0.04% |
319,544
+145,249
| +83% | +$2.22M |
|
405
HCA Healthcare
HCA
$87.2B
| $4.37M | 0.04% |
18,203
+6,690
| +58% | +$1.5M |
|
406
SiriusXM
SIRI
$9.98B
| $4.36M | 0.04% |
74,651
-38,078
| -34% | -$2.34M |
|
407
Gartner
IT
$10.1B
| $4.36M | 0.04% |
12,962
+745
| +6% | +$240K |
|
408
Huntington Ingalls Industries
HII
$12.9B
| $4.35M | 0.04% |
18,860
+4,065
| +27% | +$957K |
|
409
Norfolk Southern
NSC
$75.4B
| $4.31M | 0.04% |
17,481
+7,368
| +73% | +$1.74M |
|
410
Fate Therapeutics
FATE
$286M
| $4.3M | 0.04% |
426,583
+180,108
| +73% | +$3.38M |
|
411
Anavex Life Sciences
AVXL
$255M
| $4.3M | 0.04% |
464,754
+189,808
| +69% | +$2.03M |
|
412
Talos Energy
TALO
$2.53B
| $4.2M | 0.04% |
222,646
-13,633
| -6% | -$274K |
|
413
Globe Life
GL
$14.2B
| $4.2M | 0.04% |
34,867
+3,751
| +12% | +$429K |
|
|
AGEN
414
Agenus
AGEN
$312M
| $4.2M | 0.04% |
89,154
+18,095
| +25% | +$920K |
|
415
Pinduoduo
PDD
$126B
| $4.17M | 0.03% |
51,124
-51,361
| -50% | -$3.58M |
|
|
KYNB
416
Kyntra Bio
KYNB
$27.2M
| $4.16M | 0.03% |
10,381
+1,268
| +14% | +$486K |
|
|
DCPH
417
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $4.14M | 0.03% |
252,623
+50,570
| +25% | +$822K |
|
418
Immunovant
IMVT
$7.93B
| $4.09M | 0.03% |
+230,573
| New | +$2.9M |
|
419
3M
MMM
$90.9B
| $4.08M | 0.03% |
40,641
+19,600
| +93% | +$2M |
|
420
Kura Oncology
KURA
$800M
| $4.07M | 0.03% |
327,918
+46,004
| +16% | +$669K |
|
421
MarketAxess Holdings
MKTX
$5.71B
| $4.05M | 0.03% |
14,538
+1,591
| +12% | +$409K |
|
422
Public Storage
PSA
$60.5B
| $4.04M | 0.03% |
14,405
+5,005
| +53% | +$1.46M |
|
423
Arcus Biosciences
RCUS
$3.55B
| $4.03M | 0.03% |
195,025
-33,616
| -15% | -$925K |
|
424
Centene
CNC
$30.7B
| $3.99M | 0.03% |
48,712
+18,136
| +59% | +$1.48M |
|
425
GlobalFoundries
GFS
$27.4B
| $3.99M | 0.03% |
+74,117
| New | +$4.33M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2022 Portfolio in Review
As of Q4 2022, Rafferty Asset Management held 1,181 positions worth $11.9B, up 27% from $9.4B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Rafferty Asset Management deployed $1.81B of net new capital in Q4 2022, opening 44 new positions and adding to 774 existing holdings. Its largest new stake was Akero Therapeutics: 187,799 shares worth $10.3M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 38% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Microchip Technology, an estimated $12.3M trimmed.
- Rafferty Asset Management's largest Q4 2022 buy was Akero Therapeutics: 187,799 shares worth $10.3M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q4 2022, an estimated $294M increase.
- Rafferty Asset Management's biggest Q4 2022 reduction was Microchip Technology, cutting an estimated $12.3M.
- Rafferty Asset Management fully exited CONTINENTAL RESOURCES INC. in Q4 2022, selling an estimated $7.53M.
- Rafferty Asset Management's ten largest holdings make up 28% of its $11.9B portfolio in Q4 2022.
- Rafferty Asset Management opened 44 new positions and closed 61 in Q4 2022.
- Rafferty Asset Management's portfolio value rose 27% quarter-over-quarter to $11.9B.
Based on Rafferty Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.